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Background: Anatomical progression of pediatric inflammatory bowel disease is under-reported. The aim of this
work was to examine possible changes in the anatomical distribution of IBD in pediatric patients at diagnosis and
at follow up.
Methods: In a retrospective cohort study, the medical records of children with inflammatory bowel disease were
examined. Patients who had at least 2 endoscopic/colonoscopic examinations were included. Primary outcome was
histopathological progression based on histopathological examination of biopsies taken during endoscopic and
colonoscopic bowel examination. Factors predictive of disease progression were also examined.
Results: A total of 98 patients fulfilled inclusion criteria (49 female, 54 with ulcerative colitis, range 2 – 17 years,
mean age at diagnosis was 10.6 years, SD ± 3.67), the mean duration of follow up was 32.9 months (range 0.1 – 60
months, SD ± 8.54). In the ulcerative colitis group, 41% had disease progression and none of the examined
variables (age, gender, laboratory markers, growth and disease activity at diagnosis) appeared to effect disease
progression. In the Crohn’s disease group, 75% had disease progression. Girls (OR = 0.13, 95% CI 0.02 – 0.79) and
patients with high erythrocytic sedimentation rate (OR=0.942, 95% CI 0.894 – 0.99) were predictive for disease
progression.
Conclusions: Despite maximum therapy, the majority of children with Crohn’s disease appeared to have
histopathological disease progression. Female sex and high erythrocytic sedimentation rate seemed to be
predictive for disease progression. None of the factors analyzed seemed predictive of disease progression in
ulcerative colitis.
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Inflammatory bowel diseases (IBD), mainly ulcerative
colitis and Crohn’s disease are chronic, lifelong illnesses
with young age of onset and a great potential for mor-
bidity. The incidence of inflammatory bowel disease in
the pediatric population is increasing [1,2]. About 20%
of patients with IBD present before the age of 18 years
old [1-7]. The natural history of these diseases is influ-
enced by multiple factors of environmental and genetic
origin. IBD showing colonic involvement has been
reported to be more frequent in younger children when* Correspondence: welmatary@hsc.mb.ca
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reproduction in any medium, provided the orcompared to older children [5]. Childhood-onset Crohn’s
disease (CD) might reflect a more severe form of disease.
Older patients with ulcerative colitis (UC) have demon-
strated more cases of proctitis than younger patients
with UC [5]. The current data have suggested that IBD
may be phenotypically homogenous throughout child-
hood [8]. However, it is not clear if the histopathological
distribution of IBD varies with time or not.
The aim of this study was to examine possible change
in the histopathological distribution of IBD in pediatric
patients at diagnosis and at follow up. While examining
the anatomical distribution, the study also aimed to de-
termine the possible variables that may be associated
with or can predict change or progression in disease
distribution.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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In a retrospective cohort study, the database of children
with IBD at the Stollery Children’s Hospital, Edmonton,
Canada and medical records of children with IBD who
were 17 years of age or younger at diagnosis were exam-
ined. Patients with established clinical, endoscopic and
radiological diagnosis of IBD, following recommenda-
tions of the North American Society for Pediatric
Gastroenterology, Hepatology, and Nutrition [1], were
included consecutively. All patients were diagnosed be-
tween January 2006 and December 2008.
The following variables were recorded:
1. Patient demographics (age at diagnosis, weight and
height at diagnosis, gender, ethnicity and diagnosis)
2. Major presenting symptoms
3. Initial histopathological disease distribution at
diagnostic endoscopy/colonoscopy
4. Subsequent histopathological disease distribution at
follow up endoscopy/colonoscopy (primary outcome)
5. Initial and subsequent treatment
6. Activity indices using the Pediatric Ulcerative Colitis
Activity Index (PUCAI) and the Pediatric Crohn’s
Disease Activity Index (PCDAI) [9,10]
Definition of disease progression
Disease progression was defined as a change in histo-
pathological distribution of inflammatory bowel disease
from diagnosis to follow up based on pathology of biop-
sies taken in each endoscopy and colonoscopy.
Routine biopsies during upper gastrointestinal endos-
copy and colonoscopy were taken from lower esophagus,
gastric antrum, upper duodenum, terminal ileum (TI),
cecum, ascending colon, transverse colon, descending
colon, sigmoid colon and rectum. Two biopsies were
taken from each site. Successful intubation of TI was
established in more than 90% of patients.
Data collection
Patients eligible for the study were identified using the
pediatric IBD database and data were collected using
medical records. Inclusion criteria were children with
established diagnosis of IBD who had endoscopy/colon-
oscopy both at diagnosis and at follow up. Patients who
had one endoscopy/colonoscopy at diagnosis without
further endoscopic follow-up were excluded. Those with
incomplete charts/data were also excluded.
Outcomes
The primary outcome was disease progression at the
follow-up endoscopy/colonoscopy based on histopath-
ology. Patients were then divided into two groups:
those with disease progression and those with nodisease progression. Secondary outcome was risk fac-
tors associated with disease progression.
Statistics
Data were analyzed using Stata 9.1 (TM) (Data Analysis
and Statistical Software, Texas, USA). Summary statistics
were obtained and analyzed. Summaries (means, med-
ians, ranges and standard deviations (SDs)) were
obtained for continuous variables, while frequency distri-
butions were provided for categorical variables. Cross-
tabulations were done including all relevant variables
against the outcome variable. Factors that may be asso-
ciated with histopathological progression were explored
using logistic regression analysis. These factors included
age at diagnosis, gender, presenting symptoms, labora-
tory markers, growth parameters at diagnosis, and dis-
ease activity at diagnosis.
Results were considered statistically significant when
P < 0.05.
Ethics
The study protocol was approved by local health re-
search ethics board,
Results
During the study period, the medical records of 154 chil-
dren with IBD (mean age 11.27+/−3.74 years, 83 boys,
74 with ulcerative colitis) were examined. Ninety eight
patients fulfilled inclusion criteria (50 boys, range 2 – 17
years, mean age 10.6 years, SD ± 3.67); the mean dur-
ation of follow up was 62.9 months (range 0.1 – 60
months, SD ± 8.54). Of the 99 children with IBD, 54 had
UC (54.5 %). In the UC group, 31 were females (57.4%);
mean age of 9.9 years (SD ± 4.19)). In the Crohn’s dis-
ease group, 18 were females (40.1%); mean age was 11.2
years (SD ± 3.16).
Patients with ulcerative colitis
Of the 54 children in the ulcerative colitis group, 22
(40.7%) showed change in disease distribution from diag-
nosis till the end of the follow-up period. The distribu-
tion of disease for patients with ulcerative colitis at
diagnosis and at follow up is illustrated in Figure 1.
The most common disease distribution for the ulcera-
tive colitis group was pancolitis (38/54, 70.4%), followed
by left sided colitis extending to the splenic flexure (8/
54, 14.8%) and distal proctitis (8/54, 14.8%). Eighteen
patients (33.3%) showed evidence of disease. Of those
showing disease progression, the most common distribu-
tion was pancolitis, left sided colitis and proctitis (6/18
each, 33.3% each). Of those presenting with left sided
colitis, 3 (50%) went on to develop relative rectal sparing
pancolitis, and 3 (50%) developed pancolitis at follow up.















Figure 1 Initial histopathological disease distribution in children with ulcerative colitis.
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and 2 developed pancolitis (33.3%) at follow up.
In patients with no disease progression, the most com-
mon distribution was pancolitis (32/36, 88.9%). Two
(5.56%) had left sided colitis and 2 (5.56%) had distal
proctitis.
Demographic, laboratory and clinical characteristics of
children with ulcerative colitis are summarized in
Table 1
Age at diagnosis, gender, presenting symptoms, labora-
tory markers, growth parameters at diagnosis, and dis-
ease activity at diagnosis were not significantly different
between the two groups (disease progression vs. no dis-
ease progression). None of these variables was predictive
of disease progression in the logistic regression model.
Patients with Crohn’s disease
Of the 44 children in the Crohn’s disease group, 33
(75%) patients showed disease progression from diagno-
sis till the end of the follow-up period. The distribution
of disease at diagnosis and at follow up is illustrated in
Figure 2.
The most common disease distribution for the CD
group was terminal ileal (TI) disease (21/44 = 47.7%),
followed by upper GI disease (duodenal/stomach/
esophageal (UGI)) (17/44 = 38.6%), ileocecal/ileocolonic
disease (12/44 = 27.3%), and isolated colonic diseaseTable 1 Mean values of demographic and laboratory data of
Progression
Age at Diagnosis (years) 9.36 (
Duration of Symptoms Pre-Diagnosis (months) 3.97 (
Weight at Diagnosis (z-score) 0.28 (
Height at Diagnosis (z-score) 0.08 (
Albumin at Diagnosis (g/L) 41.18 (
ESR at diagnosis 14.91 (
AI at diagnosis 39.05 (
ESR: erythrocytic sedimentation rate, AI: activity index.(11/44 = 25.0%). Of note was that, there was an overlap
of distribution in the UGI group and only 4 of them had
an isolated UGI disease.
Thirty three patients showed evidence of disease pro-
gression (75%). Of those showing disease progression,
the most common distribution to progress was TI in-
volvement (14/33 = 42.4%). Eight out of 14 patients
(57.1%) progressed to develop ileo-colonic (without rec-
tal involvement) disease, 7 (50%) went on to develop
upper gastrointestinal (UGI) disease, 4 (28.6%) went on
to develop ileocecal disease.
In patients with no disease progression, the most com-
mon distributions were terminal ileal disease and upper
GI disease, followed by colonic disease then ileocecal
disease.
Demographic, laboratory and clinical characteristics of
children with Crohn’s disease are summarized in
Table 2.
Using logistic regression analysis, ages at diagnosis,
presenting symptoms and disease severity at diagnosis
were not significantly different between the two groups.
None of these variables was predictive of disease pro-
gression. However, it appears that there was a relation-
ship between gender (OR = 0.13, 95% CI = 0.02 – 0.79)
and disease progression. Disease progression was less
likely in girls compared to boys. Moreover, ESR at diag-
nosis was significantly higher in those who had evidencepediatric ulcerative colitis patients
Mean (SD) No Progression Mean (SD) p-value
0.96) 9.99 (0.71) 0.99
0.95) 3.94 (1.08) 0.99
0.38) −0.32 (0.37) 0.48
0.33) −0.37 (0.36) 0.37
1.10) 37.33 (1.60) 0.95
3.89) 29.88 (5.25) 0.4
3.48) 46.67 (3.72) 1.000




Disease Progression (N = 33)
TI = 14 
UGI =10 (isolated UGI = 4)
IC = 10 
C = 5
Figure 2 Initial histopathological disease distribution in children with Crohn’s disease.
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ease progression and was predictive of disease progres-
sion (OR=0.94, 95% CI 0.90 – 0.99).
Discussion
Our study examined histopathological changes in the
distribution of IBD from diagnosis through follow-up in
children and attempted to determine factors that would
influence the progression of inflammatory bowel disease
in this population.
The initial disease histopathological distribution in
those ulcerative colitis patients with disease progression
in our study was similar to those in previous studies, cit-
ing pancolitis, left sided colitis and proctitis as the most
common distributions [1,3,4,7,8,11]. For the ulcerative
colitis population, 40.7% of our patients showed disease
progression. It appears that there is no relationship to
age, duration of symptoms pre-diagnosis, weight, height,
serum albumin levels, ESR and disease activity index at
diagnosis. Interestingly, some patients with pancolitis in
our series, who did not have any evidence of upper
gastrointestinal involvement on initial endoscopy, had
evidence of histopathological abnormalities on follow-up
endoscopy. Upper gastrointestinal involvement in chil-
dren with UC has been previously reported [12].
The most common initial disease histopathological
involvements of Crohn’s disease in our study were ter-
minal ileum, ileocecal and upper GI involvement. ThisTable 2 Mean values of demographic and laboratory data of
Disease Progres
Age (years) 11.01





AI at diagnosis 30.65
ESR: erythrocytic sedimentation rate, AI: activity index.finding agreed with previous studies which found that
50 – 70% of their pediatric CD patients had TI involve-
ment at presentation [7,13,14]. About 75% of the CD
patients in our study showed disease progression. It
appears that there is a significant relationship between
sex (OR = 0.13, 95% CI = 0.02 – 0.79) and disease pro-
gression. Based on our analysis, it appears that disease
progression is less likely with those patients who are fe-
male when compared to those that are male. However, a
previous study by Freeman demonstrated that CD
tended to be more prominent in females when com-
pared to their male counterparts [14]. Interestingly, in a
previous study, it was determined that the switch to a fe-
male predominance began at around the age of adoles-
cence [15]. It also appears that there is a significant
relationship between ESR at diagnosis and disease pro-
gression in Crohn’s disease patients. Disease progression
is more likely in those Crohn’s disease patients that have
a higher ESR at diagnosis than those with a lower ESR
at diagnosis. There are no previous studies to which we
can compare these results.
Although we attempted to optimize the results
obtained from our retrospective chart review, our study
was limited in a few areas. Firstly, our study defined dis-
ease progression strictly as histopathological changes in
disease distribution from diagnosis to follow up. Al-
though this definition served the purpose of our study,
perhaps future research could also look into diseasepediatric Crohn’s disease patients
sion Mean (SD) No Disease Progression Mean (SD) p-value
(0.60) 11.52 (0.58) 0.7
(1.54) 8.83 (4.80) 0.83
(0.37) 0.05 (0.85) 0.28
(0.35) −0.29 (0.71) 0.06
(1.37) 35.88 (1.64) 0.32
(5.47) 27.50 (4.43) 0.02
(2.59) 31.67 (2.04) 0.34
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symptoms, and whether or not factors affecting the clin-
ical presentation and symptoms can predict IBD pro-
gression. Of note is that, large areas of small bowel
could not normally be biopsied to explore histopatho-
logical involvement of Crohn’s disease.
Secondly, our study excluded those patients that did
not have colonoscopy/endoscopy at follow up. Although
that was necessary for the purpose of our study, perhaps
future studies could look at disease status at follow up in
another sense (to increase the number of IBD subjects
available for the study). One can argue that patients with
less controlled disease will be more likely to be scoped
and hence selection bias is more likely to take place.
Thirdly, for the purpose of our study, our subjects were
divided into 2 main categories: disease progression and
no disease progression. Future studies may benefit by
further dividing the disease presentation and progression
categories into mild, moderate and severe disease. In this
sense, there may be a better understanding of which fac-
tors may affect certain stages of IBD in children.
Conclusions
Despite maximum therapy, the majority of children with
Crohn’s disease appeared to have disease progression.
Female sex and high erythrocytic sedimentation rate
seemed to be predictive for disease progression. None of
the factors analyzed seemed predictive of disease pro-
gression in ulcerative colitis.
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